Short-term effects of Lumacaftor/Ivacaftor (Orkambi™) on exertional symptoms, exercise performance, and ventilatory responses in adults with cystic fibrosis

Short-term effects of Lumacaftor/Ivacaftor (Orkambi™) on exertional symptoms, exercise performance, and ventilatory responses in adults with cystic fibrosis

Abstract Rationale Lumacaftor/ivacaftor (LUM/IVA) modestly improves lung function following 1 month of treatment but it is unknown if this translates into improvements in exercise endurance and exertional symptoms. Methods Adult CF participants completed a symptom-limited constant load cycling test...

Full description

Bibliographic Details
Main Authors: Bradley S. Quon, Andrew H. Ramsook, Satvir S. Dhillon, Reid A. Mitchell, Kyle G. Boyle, Pearce G. Wilcox, Jordan A. Guenette
Format: Article
Language:English
Published: BMC 2020-06-01
Series:Respiratory Research
Online Access:http://link.springer.com/article/10.1186/s12931-020-01406-z

Internet

http://link.springer.com/article/10.1186/s12931-020-01406-z

Similar Items